Miniatura

Fitxers

731692.pdf (1.56 MB)

Tipus de document

Article

Versió

Versió acceptada

Data de publicació

2022-12

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/194390

HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1093/jnci/djac227

Resum

In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown. Biomarkers to guide the use of anti-HER2 therapies beyond HER2 status are needed. Here, we evaluated if pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay are associated with response and survival following T-DM1. In ERBB2 low, medium, and high groups, the overall response rate was 0%, 29% and 56%, respectively (P<.001). ERBB2 mRNA was significantly associated with better progression-free survival (p = 0.002) and overall survival (OS; P = 0.02). These findings were independent of HER2 IHC levels, hormone receptor, age, brain metastasis and line of therapy. The HER2DX risk-score (P=.04) and the immunoglobulin (IGG) signature (P=.04) were significantly associated with OS since diagnosis. HER2DX provides prognostic and predictive information following T-DM1 in advanced HER2+ BC.

Matèries

Tumors cerebrals, Metàstasi, Càncer de mama, Expressió gènica, Cèl·lules T

Matèries (anglès)

Brain tumors, Metastasis, Breast cancer, Gene expression, T cells

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

BRASÓ MARISTANY, Fara, GRIGUOLO, Gaia, CHIC RUCHÉ, Núria, PASCUAL, Tomás, PARÉ BRUNET, Laia, MAUES, Julia, GALVÁN, Patricia, DIECI, Maria vittoria, MIGLIETTA, Federica, GIARRATANO, Tommaso, MARTÍNEZ SÁEZ, Olga, MARÍN AGUILERA, Mercedes, SCHETTINI, Francesco, CONTE, Benedetta, ANGELATS, Laura, VIDAL LOSADA, Maria jesús, ADAMO, Barbara, MUÑOZ, Montse, SANFELIU, Esther, GONZÁLEZ FARRÉ, Blanca, VIVANCOS, Ana, VILLAGRASA, Patricia, PARKER, Joel s., PEROU, Charles m., CONTE, Pierfranco, PRAT APARICIO, Aleix, GUARNERI, Valentina. HER2DX ERBB2 mRNA expression in advanced HER2- positive breast cancer treated with T-DM1. _JNCI: Journal of The National Cancer Institute_. 2022. [consulta: 5 de febrer de 2026]. ISSN: 0027-8874. [Disponible a: https://hdl.handle.net/2445/194390]

Exportar metadades

JSON - METS

Compartir registre